We are live on ! Find out more
SPRB

Spruce Biosciences

31 hedge funds and large institutions have $4.69M invested in Spruce Biosciences in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

7% more funds holding

Funds holding: 2931 (+2)

27% less capital invested

Capital invested by funds: $6.41M → $4.69M (-$1.71M)

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
31
Holders Change
+2
Holders Change %
+6.9%
% of All Funds
0.41%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
7
Increased
4
Reduced
8
Closed
4
Calls
$9K
Puts
Net Calls
+$9K
Net Calls Change
+$1K
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$896
Group One Trading
27
Group One Trading
Illinois
$743 -$990 -27 -53%
CSC
28
Caldwell Sutter Capital
California
$420
Bank of America
29
Bank of America
North Carolina
$93
BNP Paribas Financial Markets
30
BNP Paribas Financial Markets
France
$76 +$73 +2 New
JP Morgan Chase
31
JP Morgan Chase
New York
$29
AC
32
Almitas Capital
California
-$188K -5,287 Closed
Citadel Advisors
33
Citadel Advisors
Florida
-$36.6K -1,027 Closed
Jane Street
34
Jane Street
New York
-$7.44K -209 Closed
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
-$2K -50 Closed

SPRB Hedge Fund Activity: Q4 2024 in Review

31 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q4 2024, worth a combined $4.69M — down 27% from $6.41M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new SPRB positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $489K. The largest seller was Almitas Capital, exiting entirely with an estimated $188K sold.

  • 31 institutional investors held Spruce Biosciences (SPRB) as of Q4 2024, up from 29 in Q3 2024.
  • Funds reported $4.69M of Spruce Biosciences stock for Q4 2024, down 27% quarter-over-quarter.
  • 7 funds opened new Spruce Biosciences positions in Q4 2024 and 4 closed out, a net change of +3 holders.
  • The largest Spruce Biosciences buyer in Q4 2024 was Ikarian Capital, an estimated $489K added.
  • The largest Spruce Biosciences seller in Q4 2024 was Almitas Capital, an estimated $188K sold.

Based on aggregated 13F filings for Q4 2024.